



## Milestone® Pharmaceuticals to Present at the Upcoming BTIG Virtual Biotechnology Conference

July 31, 2024

MONTREAL and CHARLOTTE, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will participate in the BTIG Virtual Biotechnology Conference, to take place from August 5-6, 2024.

A live webcast of the fireside chat will be available to conference participants on August 6th at 8 AM EDT. If you are interested in viewing the fireside chat or meeting with the Milestone team during the conference, email [uscorporateaccess@btig.com](mailto:uscorporateaccess@btig.com).

### About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company's focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.

### Contact:

Kim Fox, Vice President, Communications, [kfox@milestonepharma.com](mailto:kfox@milestonepharma.com)

### Investor Relations

Chris Calabrese, [ccalabrese@lifesciadvisors.com](mailto:ccalabrese@lifesciadvisors.com)

Kevin Gardner, [kgardner@lifesciadvisors.com](mailto:kgardner@lifesciadvisors.com)



Source: Milestone Pharmaceuticals Inc.